Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Adenoviral-Mediated Suicide Gene Therapy for Ovarian Cancer

1 Nov 2000

Abstract excerpt

The purpose of this phase I study was to determine the potential efficacy of adenoviral-mediated suicide gene therapy in women with recurrent ovarian cancer. Fourteen patients were treated intraperitoneally with herpes simplex virus-thymidine kinase (HSV-TK)-encoding adenovirus (AdHSV-TK) in dosages ranging between 1x10(9) and 1x10(11) pfu. Beginning 2 days later, ganciclovir (GCV) was administered intravenously...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Research and Treatments
Share to Viral gastroenteritis research and epidemiology
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 11082326
DOI: 10.1006/mthe.2000.0194

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Adenoviral-Mediated Suicide Gene Therapy for Ovarian CancerPMID 11082326Read ↗

A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.Semantic proximity Read ↗

Gene therapy and ovarian cancer: a review.Semantic proximity Read ↗

From gene therapy to virotherapy for ovarian cancer.Semantic proximity Read ↗

Adenovirus-based p53 gene therapy in ovarian cancer.Semantic proximity Read ↗

Gene therapy: ovarian carcinoma as the paradigm.Semantic proximity Read ↗

Phase I Trial of Intraperitoneal Injection of the E1B-55-kd-Gene-Deleted Adenovirus ONYX-015 (dl1520) Given on Days 1 Through 5 Every 3 Weeks in Patients With Recurrent/Refractory Epithelial Ovarian CancerSemantic proximity Read ↗

Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status.Semantic proximity Read ↗

Adenovirus-mediated tumor suppressor p53 gene therapy for anaplastic thyroid carcinoma in vitro and in vivo.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.